Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association

키워드

참고문헌 (57)

1. 고승현, "2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea", Diabetes and Metabolism Journal, 35(5), pp.431~436 (2011), 대한당뇨병학회
2. 민경완, "Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial", Diabetes and Metabolism Journal, 41(2), pp.135~145 (2017), 대한당뇨병학회[DOI]
3. 김종호, "Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin", Diabetes and Metabolism Journal, 40(3), pp.230~239 (2016), 대한당뇨병학회[DOI]
4. Yoon KH, "Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials", Diabetes Obes Metab, 18, pp.1045~1049 (2016)
5. 윤건호, "Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus", Diabetes and Metabolism Journal, 41(1), pp.69~74 (2017), 대한당뇨병학회[DOI]
6. American Diabetes Association., "Standards of medical care in diabetes: 2017", Diabetes Care, 40(Suppl 1), pp.S1~S135 (2017)
7. UK Prospective Diabetes Study (UKPDS) Group., "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
8. Garber AJ, "Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm:2017 executive summary", Endocr Pract, 23, pp.207~238 (2017)
9. McGuire H, "Management of type 2diabetes in adults: summary of updated NICE guidance", BMJ, 353, pp.i1575~ (2016)
10. Inzucchi SE, "Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 38, pp.140~149 (2015)
11. 김정민, "Factors Associated with Participation in Diabetes Education: The Korea National Health and Nutrition Examination Survey 2007 to 2009", Diabetes and Metabolism Journal, 40(6), pp.447~453 (2016), 대한당뇨병학회[DOI]
12. 용윤미, "Intensive Individualized Reinforcement Education Is Important for the Prevention of Hypoglycemia in Patients with Type 2 Diabetes", Diabetes and Metabolism Journal, 39(2), pp.154~163 (2015), 대한당뇨병학회
13. Kyoung Hwa Ha, "Current status of managing diabetes mellitus in Korea", The Korean Journal of Internal Medicine, 31(5), pp.845~850 (2016), 대한내과학회[DOI]
14. 전숙, "An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass", Diabetes and Metabolism Journal, 40(2), pp.99~114 (2016), 대한당뇨병학회[DOI]
15. Turner RC, "Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)", JAMA, 281, pp.2005~2012 (1999), UK Prospective Diabetes Study (UKPDS) Group
16. Sherifali D, "The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis", Diabetes Care, 33, pp.1859~1864 (2010)
17. UK Prospective Diabetes Study (UKPDS) Group., "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)", Lancet, 352, pp.854~865 (1998)
18. Maruthur NM, "Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis", Ann Intern Med, 164, pp.740~751 (2016)
19. Palmer SC, "Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis", JAMA, 316, pp.313~324 (2016)
20. Esposito K, "Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials", BMJ Open, 4, pp.e005442~ (2014)
21. Storgaard H, "Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis", PLoS One, 11, pp.e0166125~ (2016)
22. 윤재승, "Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus", Diabetes and Metabolism Journal, 40(6), pp.423~432 (2016), 대한당뇨병학회[DOI]
23. 차선아, "Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes", Diabetes and Metabolism Journal, 40(3), pp.202~210 (2016), 대한당뇨병학회[DOI]
24. 윤건호, "Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study", Diabetes and Metabolism Journal, 35(1), pp.26~33 (2011), 대한당뇨병학회
25. Foroutan N, "Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis", Clin Invest Med, 39, pp.E48~E62 (2016)
26. Zhong X, "Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis", Eur J Clin Pharmacol, 72, pp.655~663 (2016)
27. Mishriky BM, "The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2diabetes: a systematic review and meta-analysis", Diabetes Res Clin Pract, 109, pp.378~388 (2015)
28. Zhou JB, "The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial", Int J Clin Pract, 70, pp.132~141 (2016)
29. Del Prato S, "Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data", Diabetes Obes Metab, 17, pp.581~590 (2015)
30. Kim YG, "Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians:a systematic review and meta-analysis", Diabetologia, 56, pp.696~708 (2013)
31. Mearns ES, "Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes:a network meta-analysis", Diabet Med, 32, pp.1530~1540 (2015)
32. Taylor SI, "SGLT2 inhibitors may predispose to ketoacidosis", J Clin Endocrinol Metab, 100, pp.2849~2852 (2015)
33. 오승준, "The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea", Diabetes and Metabolism Journal, 39(3), pp.177~187 (2015), 대한당뇨병학회[DOI]
34. Kim MK, "Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes", Diabetes Res Clin Pract, 92, pp.322~328 (2011)
35. Olansky L, "A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents", Diabetes Obes Metab, 13, pp.841~849 (2011)
36. Phung OJ, "Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis", Diabetes Obes Metab, 16, pp.410~417 (2014)
37. Varvaki Rados D, "The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials", PLoS Med, 13, pp.e1001992~ (2016)
38. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)
39. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
40. Hwang YC, "The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes:sub-analysis from the A(1)chieve(R) study", Int J Clin Pract, 68, pp.1338~1344 (2014)
41. Malmberg K, "Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study", Circulation, 99, pp.2626~2632 (1999)
42. Griesdale DE, "Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data", CMAJ, 180, pp.821~827 (2009)
43. Fonseca V, "An analysis of early insulin glargine added to metformin with or without sulfonylurea:impact on glycaemic control and hypoglycaemia", Diabetes Obes Metab, 13, pp.814~822 (2011)
44. Park CY, "Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes", PLoS One, 9, pp.e87799~ (2014)
45. Zhong X, "Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and", or a sulfonylurea: a network meta-analysis, 2015, pp.109, 451~460
46. Horvath K, "Long-acting insulin analogues versus NPH insulin (human isophane insulin)for type 2 diabetes mellitus", Cochrane Database Syst Rev, (2), pp.CD005613~ (2007)
47. Russell-Jones D, "Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials", Nutr Metab Cardiovasc Dis, 25, pp.898~905 (2015)
48. Marso SP, "Efficacy and safety of degludec versus glargine in type 2 diabetes", N Engl J Med, 377, pp.723~732 (2017)
49. Yki-Jarvinen H, "Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study", Diabetes Care, 36, pp.3875~3881 (2013)
50. Kothny W, "Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus", Diabetes Obes Metab, 15, pp.252~257 (2013)
51. Hong ES, "Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes:CSI study", Diabetes Obes Metab, 14, pp.795~802 (2012)
52. Min SH, "Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis", Diabetes Metab Res Rev, 33, pp.e2818~ (2017)
53. Giugliano D, "Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes:a systematic review and meta-analysis of randomized controlled trials", Endocrine, 51, pp.417~428 (2016)
54. Diamant M, "Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes", Diabetes Care, 37, pp.2763~2773 (2014)
55. Eng C, "Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2diabetes: a systematic review and meta-analysis", Lancet, 384, pp.2228~2234 (2014)
56. Mathieu C, "A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)", Diabetes Obes Metab, 16, pp.636~644 (2014)
57. 최성희, "Comparison of Antidiabetic Regimens in Patients with Type 2 Diabetes Uncontrolled by Combination Therapy of Sulfonylurea and Metformin: Results of the MOHAS Disease Registry in Korea", Diabetes and Metabolism Journal, 41(3), pp.170~178 (2017), 대한당뇨병학회[DOI]

관련 논문AI추천